With Third Quarter Results, Biogen Idec Continues to Ride Its Warhorse Avonex

Q3 results were strong, thanks to Avonex, but new competition from Novartis' oral MS therapy Gilenya and dwindling Rituxan royalties from Roche threaten longer-term outlook.